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microvascular and macrovascular complications and increased mortality. [3] [4] [5] According to recent statistics, only 30% of adults with T1DM achieve the HbA1c goal of 7% recommended by the American Diabetes Association. 1 These findings clearly emphasize the need for new treatments-adjuncts to existing insulin therapy for patients with T1DM that will help maintain glycaemic control and potentially reduce unwanted side effects of insulin. 6, 7 Currently, the only adjunct to insulin therapy approved by the US Food and Drug Administration for T1DM is the amylin analogue pramlintide. 8 Other glucose-lowering agents tested in patients with T1DM
include glucagon-like peptide-1 receptor agonists, 9 dipeptidyl peptidase-4 inhibitors, 10 and sodium-glucose cotransporter-2 (SGLT2)
inhibitors. [11] [12] [13] SGLT2 inhibitors, such as dapagliflozin, are an attractive adjunct to insulin treatment for patients with T1DM as they improve glycaemic control independently from insulin by lowering the renal threshold for glucose and increasing urinary glucose excretion.
In addition to lowering glucose levels, SGLT2 inhibitors have been shown to have further benefits, including body weight loss, blood pressure reduction, and cardiovascular and renal benefits in patients with type 2 diabetes mellitus (T2DM). [14] [15] [16] [17] Dapagliflozin, approved
for treatment of T2DM, may also be effective in patients with T1DM.
In a short pilot study among patients with T1DM, treatment with dapagliflozin resulted in dose-dependent urinary glucose excretion. . 11, 18 While the relationship between dapagliflozin systemic exposure and urinary glucose excretion was well characterized during a previous quantitative assessment, 19 the exposure-HbA1c response of dapagliflozin in patients with T1DM has not yet been described. This analysis used HbA1c data collected during two phase 3 studies of dapagliflozin to quantitatively assess this exposure-response relationship and to explore whether certain covariates have an impact on HbA1c response among patients with T1DM. Such quantitative understanding obtained by describing exposure-response properties of a drug is valuable because it increases knowledge about drug effects in specific patient populations and can be used to inform decisions such as selecting the most appropriate dosing regimen. The main purpose and value of the covariate assessment is to identify potential patients that can benefit most from the treatment. 20 2 | MATERIALS AND METHODS
| Data
Data were pooled from two randomized, double-blind phase 3 studies of dapagliflozin in patients with T1DM [DEPICT-1 (ClinicalTrials.gov identifier: NCT02268214) and DEPICT-2 (NCT02460978)] who received dapagliflozin 5 or 10 mg or placebo over 24 weeks (Table S1 ). All patients were treated with their existing insulin therapy in addition to the study medication. It was recommended that patients reduce their daily insulin dose up to 20% for both basal and bolus insulin the day before or during the first day of treatment with the study medication. Following a recommendation to reduce insulin dose at randomization and subsequently to attempt up-titration, patients were instructed to adjust their insulin doses based on blood glucose 
| Model development
A non-linear mixed effect modeling approach was used. In this approach, a mixed-effects model for repeated measures with an exposure-response E max component was used to describe the longitudinal HbA1c data in patients with T1DM. In this model, the HbA1c response at a given visit (k) was dependent on HbA1c at baseline, the placebo effect at the given visit, and the drug effect at the given visit, described by the following equation:
where BL corresponds to HbA1c at baseline and Placebo k and Eff k correspond to the placebo effect and the drug effect at visit k, respectively. The placebo effect was described separately for each study. The drug effect at visit k was described using a maximum effect (E max ) function:
where E max,k is the maximum HbA1c effect at visit k and EAUC 50 is the exposure (AUC) at which one half of E max is achieved.
The final outputs from the model were a set of five E max,k variables, which correspond to the maximum drug effect at weeks 4, 8, 12, 18 , and 24, a set of 10 Placebo k variables, which correspond to the placebo effect for each study at each visit, and one EAUC 50 variable.
Between-patient variability for exposure-response variables was evaluated using the log-normal distribution (normal distribution with a mean of 0 and a variance equal to ω2). 22 Residual variability was modelled using an additive error model.
| Model selection and validation
Discrimination between models was primarily based on the inspection of graphical diagnostics and changes in the objective function value (OFV) provided by NONMEM (GloboMax, Hanover, Maryland). The adequacy of the models was evaluated using graphical analysis of goodness-of-fit plots and visual predictive checks. 23 
| Covariate analysis
The covariates assessed in the analysis were selected based on prior knowledge of the mechanism of action of dapagliflozin, previous exposure-response models developed for dapagliflozin in patients with T2DM, and exposure-response models developed for urinary glucose excretion in patients with T1DM. The following covariates were assessed during the modeling analysis: baseline HbA1c, estimated glomerular filtration rate, reduction in total insulin dose at week 24 relative to baseline insulin dose, age, sex, body weight, race (Asian vs. nonAsian), and method of insulin administration (multiple daily injections vs. continuous subcutaneous insulin infusion by insulin pump). All covariates were tested on the dapagliflozin E max and EAUC 50 variables.
None of the patients had missing baseline covariate values.
Baseline average daily glucose levels at weeks 14 and 24 from continuous glucose monitoring (CGM) were explored as a potential covariate. However, they were found to be correlated to baseline CGM values; additionally, these variables were also missing in some patients (11% and 17.5% for CGM at weeks 12 and 24, respectively). For these reasons, CGM was not included in the covariate assessment.
During the covariate analysis, covariates were identified using a stepwise covariate modelling procedure, as implemented within PsN 
| Model predictions
Prediction uncertainty was derived, accounting for model variable uncertainty. In brief, a large set of variable combinations was simulated (n = 10 000) using mean variable values and the covariance matrix. Next, a model prediction (i.e. HbA1c reduction at week 24 predicted for a given AUC value) was derived for each variable combination; this resulted in 10 000 simulated outcomes (HbA1c reduction) that were then used to calculate a median prediction with a 95% confidence interval (CI; calculated as median and 2.5% and 97% quintile of the distribution). Median values of the covariates were used in the simulations. All simulations were performed in R (R-project, www.rproject.org) using the nonmem2R package (https://CRAN.R-project.
org/package=nonmem2R).
| Software
The software package NONMEM version 7.3.0 (GloboMax, Hanover, Maryland) was used in this analysis. Maximum likelihood inference was performed using the conditional first-order approximations (with interaction). PsN version 4.2.0 (psn.sourceforge.net) and R version 3.0 (R-project, www.r-project.org) were used for the exploratory analysis and postprocessing of NONMEM outputs (e.g. to assess goodnessof-fit).
3 | RESULTS
| Patient characteristics
Data from a total of 1591 patients with T1DM were used in this analysis (DEPICT-1, n = 778; DEPICT-2, n = 813); the number of patients/samples for each arm is shown in Table S2 . Baseline characteristics of the patients are presented in 
| Pharmacokinetics and pharmacodynamics of dapagliflozin
Dapagliflozin exposure (AUC) and HbA1c response following corresponding doses were similar in both studies. Mean steady-state AUC and placebo-corrected change in HbA1c from baseline at week 24 for dapagliflozin 5-and 10-mg doses are shown for both studies in Table 2 . Mean placebo-corrected change in HbA1c from baseline by study week and stratified by dose is presented in Figure 1 . In both studies, dapagliflozin treatment resulted in reduced insulin doses in both 5-and 10-mg treatment arms (see Figure S1 ). Table S4 .
The model-predicted HbA1c responses at week 24 for dapagliflozin 5-and 10-mg doses were − 0.42 (95% CI -0.47, −0.36) and − 0.45 (95% CI -0.5, −0.4), respectively, which was in very good agreement with the observed clinical data. This can be seen in Figure 2B , which shows the derived dose-response relationship (simulated using the final exposure-response model) overlaid with the actual data from both phase 3 studies.
| DISCUSSION
The phase 3 DEPICT-1 and DEPICT-2 studies showed statistically significant and clinically relevant reductions in HbA1c among patients with T1DM with dapagliflozin compared with placebo following 24 weeks of treatment. This was accompanied by significant reductions in total daily insulin doses. 11, 18 This analysis quantitatively Model−predicted median E max effect ratio greater effects seen among patients with higher baseline HbA1c. [24] [25] [26] [27] Interestingly, daily insulin dose reduction was not found to be a significant covariate on dapagliflozin efficacy. This was somewhat surprising because T1DM patients treated with dapagliflozin in both phase 3 studies were observed to have significant reductions in their daily insulin doses 11, 18 ( Figure S1 ), which would have an impact on the HbA1c levels.
It is anticipated that the overall HbA1c reductions observed in T1DM
patients following dapagliflozin or other SGLT2 inhibitor treatment is a combination of a direct effect of the drug (through urinary glucose excretion) and an effect mediated via reduction in insulin dose. The impact of insulin dose reduction on SGLT2 inhibitor efficacy has been previously described in terms of urinary glucose excretion, where T1DM patients who had greater total insulin dose reduction were also observed to have a more pronounced urinary glucose excretion response. 28, 29 It is unclear why a similar covariate effect was not identified in the current analysis.
One explanation may be that systematic insulin dose reduction data collected in the phase 3 trials were too limited (i.e. not available for every timepoint where HbA1c was measured).
Because it was not possible to "untangle" the combined effect of Although it was not possible to untangle the combined effect of dapagliflozin and insulin dose reduction on HbA1c response in the current analysis, we believe that there is additional information from T1DM studies that could help us understand this complexity. For example, in both phase 3 T1DM studies, there appears to be a greater difference between dapagliflozin doses with regard to body weight change (that would reflect caloric losses in the urine), than the effect on HbA1c. 11, 18 This supports the suggestion that while the 10 mg dapagliflozin dose may have an intrinsically greater effect, its glycae- 
